| CBV | |
| Specialty: | oncology |
CBV refers to Cytoxan (cyclophosphamide), BCNU (carmustine), and VP-16 (etoposide), three drugs in a chemotherapy regimen commonly given to lymphoma patients in conjunction with stem cell therapy.[1]
CBV is usually given in high doses to patients who have relapsed or who have refractory disease and cannot benefit from standard chemotherapy. Since a patient's bone marrow is virtually guaranteed not to survive a course of CBV, the receiving patient must receive a transplant (allogeneic or autologous, depending on his or her condition) of stem cells (formerly referred to as a bone marrow transplant) to replace the patient's own hemopoietic ("blood-forming") stem cells.[2]